Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
VSTM2L CRISPR Activation Plasmid (h): sc-414330-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- VSTM2L CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- VSTM2L CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by VSTM2L CRISPR Activation Plasmid (h) and VSTM2L CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the VSTM2L transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: VSTM2L Antibody (A-4): sc-376538
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VSTM2L CRISPR Activation Plasmid (h) | sc-414330-ACT | 20 µg | $397.00 | |||
VSTM2L CRISPR Activation Plasmid (h2) | sc-414330-ACT-2 | 20 µg | $397.00 |
VSTM2L (V-set and transmembrane domain containing 2 like) encodes a membrane-associated protein with a V-set immunoglobulin-like domain that is enriched in neural tissues and implicated in cell–cell communication and extracellular signaling. Reported expression patterns and functional studies link VSTM2L to neuronal differentiation and synaptic processes, suggesting roles in regulating neurodevelopmental programs and neuronal network activity. As a surface/secreted-associated factor, VSTM2L is frequently investigated in pathways governing intercellular signaling, transcriptional regulation downstream of receptor-mediated cues, and tissue-specific gene expression. Dysregulated VSTM2L expression has been explored as a molecular feature in neurological and neuropsychiatric research contexts and in broader studies of brain-linked transcriptional signatures.
VSTM2L CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous VSTM2L expression without altering the underlying DNA sequence.
VSTM2L CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the VSTM2L locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the VSTM2L transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous VSTM2L expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native VSTM2L locus and enabling the study of VSTM2L-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of VSTM2L pathway restoration in tumor cells with silenced or reduced VSTM2L expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.